BOSTON – Allarity Therapeutics, Inc. (NASDAQ: ALLR), a micro-cap biopharmaceutical company valued at $4.79 million, has announced a new protocol for its ongoing clinical trial of stenoparib, a potential treatment for advanced ovarian cancer. According to InvestingPro analysis, the company’s stock has declined over 99% in the past year, though current metrics suggest it may be undervalued relative to its potential. The protocol aims to refine…